A CLINICAL TRIAL ON â??IRATHAK KAARIYA KULIKAIâ?? IN THE MANAGEMENT OF â??NEERILIVUâ??(DIABETES MELLITUS)

A PROSPECTIVE OPEN LABELLED, PHASE II, NON- RANDOMIZED, CLINICAL TRIAL ON â??IRATHAK KAARIYA KULIKAIâ?? IN THE MANAGEMENT OF â??NEERILIVUâ??(DIABETES MELLITUS)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/01/030591

Enrollment

Registered

2021-01-19

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E11- Type 2 diabetes mellitus

Interventions

Intervention1: IRATHAK KAARIYA KULIKAI: 1 tablet (130mg) twice a day after meals with aavarai kudineer for 45 days in 40 patients Control Intervention1: N/A: N/A

Eligibility

Inclusion criteria

Inclusion criteria: Type II Diabetes mellitus, previously diagnosed diabetic patients.

Exclusion criteria

Exclusion criteria: Type I Diabetes mellitus Gestational Diabetes mellitus Lactating mother Smoking / Alcohol Have a history of frequent and/or severe allergic reactions with multiple medications.

Design outcomes

Primary

Measure	Time frame
Fasting Blood sugar level and complaints have been reduced during treatment or after treatmentTimepoint: 1 year	—

Secondary

Measure	Time frame
Find out the pre clinical study of the trail drug. Evaluate the efficacy of IRATHAK KAARIYA KULIKATimepoint: 1 year	—

Countries

India

Contacts

Public ContactDr S Sundararajan

Government Siddha Medical College & Hospital

drvictoriathangaraj@gmail.com9444109971

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026